We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome-Wide Analysis Pinpoints Cancer Cell Genes Linked to Metastasis and Chemotherapy Susceptibility

By LabMedica International staff writers
Posted on 02 May 2013
Print article
Cancer researchers used genome-wide analyses to investigate the link between gene expression and anticancer compound sensitivity and cancer cell invasion.

Investigators at Academia Sinica (Taipei, Taiwan, Republic of China) and the National Taiwan University College of Medicine (Taipei, Republic of China) utilized the [US] National Cancer Institute's (Bethesda, MD, USA) panel of 60 tumor cell lines to gain insights on the genetic mechanism of drug sensitivity and on the contributing molecular factors to invasion heterogeneity. The NCI-60 human tumor cell line anticancer drug screen was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumors in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumor-cell kill.

In the current study, the investigators identified invasion-associated (IA) genes by correlating their invasion profiling data with the Affymetrix gene expression data on NCI-60. They then employed the recently released chemosensitivity data of 99 anticancer drugs of known mechanism to investigate the gene-drug correlation, focusing on the IA genes. Afterwards, they collected data from four independent drug-testing experiments to validate the findings on compound response prediction. Finally, they obtained published clinical and molecular data from two recent adjuvant chemotherapy cohorts, one on lung cancer and one on breast cancer, to test the performance of their gene signature for patient outcome prediction.

Results published in the April 16, 2013, online edition of the journal BMC Medicine identified 633 IA genes from the invasion-gene expression correlation study. For each of the 99 drugs, the investigators obtained a subset of IA genes whose expression levels correlated with drug-sensitivity profiles. They identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32, and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib. This eight-gene signature for chemosensitivity prediction was validated by a total of 107 independent drug tests on 78 tumor cell lines, most of which were outside of the NCI-60 panel.

The eight-gene signature predicted relapse-free survival for the lung and breast cancer patients and featured the cancer hallmark epidermal growth factor receptor (EGFR) and genes involved in cell adhesion, migration, invasion, tumor growth, and progression.

Senior author Dr. Ker-Chau Li, professor of statistical science at Academia Sinica, said, "Our study found eight genes which were involved in invasion, and the relative activation of these genes correlated to chemotherapy outcome, including the receptor for growth factor EGF. We also found that some invasion genes had unique patterns of expression that reflect the differential cell responses to each of the chemotherapy agents - five drugs (paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib) had the greatest effect."

Contributing author Dr. Pan-Chyr Yang, professor of medicine at National Taiwan University, said, "The discovery of prognostic biomarkers for chemotherapy patients remains critical toward improving the efficacy of cancer treatment. The eight-gene signature obtained here may help choice of treatment as part of individualized cancer therapy and our method of gene discovery may be applicable in studying other cancers."

Related Links:

Academia Sinica
National Taiwan University College of Medicine
National Cancer Institute



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.